Alphamab Oncology (HKSE:09966) Pre-Tax Income : HK$-230.3 Mil (TTM As of Dec. 2023)

Alphamab Oncology Pre-Tax Income Chart

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial								-177.61	-172.68	-199.24	-43.60	-186.74

Competitive Comparison of Alphamab Oncology's Pre-Tax Income

For the Biotechnology subindustry, Alphamab Oncology's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Pre-Tax Income falls into.

Alphamab Oncology Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Alphamab Oncology's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Alphamab Oncology's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-230.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology  (HKSE:09966) Pre-Tax Income Explanation

Alphamab Oncology's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

During the past 7 years, Alphamab Oncology's highest Pretax Margin was -96.26%. The lowest was -282.44%. And the median was -195.22%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description